{
    "clinical_study": {
        "@rank": "38731", 
        "brief_summary": {
            "textblock": "OBJECTIVES: I.  Evaluate the efficacy of related, HLA-identical bone marrow transplantation\n      following cyclophosphamide (CTX) and antithymocyte globulin in patients with aplastic\n      anemia.\n\n      II.  Evaluate the efficacy of related, HLA-nonidentical bone marrow transplantation\n      following CTX and total-body irradiation/total-lymphoid irradiation in patients with\n      aplastic anemia."
        }, 
        "brief_title": "Phase II Study of Bone Marrow Transplantation Using Related Donors in Patients With Aplastic Anemia", 
        "condition": "Aplastic Anemia", 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Anemia, Aplastic"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: Patients with HLA-identical donors receive cyclophosphamide/mesna,\n      antithymocyte globulin (ATG), and methylprednisolone (MePRDL), followed by allogeneic marrow\n      transplantation.\n\n      Patients with HLA-nonidentical (5/6 or 4/6) donors and those with a systemic reaction to ATG\n      receive the same dosage of myeloablative chemotherapy and rescue.  In addition, these\n      patients are treated with total-body irradiation, total-lymphoid irradiation, and\n      methotrexate.\n\n      All patients received MePRDL and cyclosporine for graft-versus-host prophylaxis."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics-- Severe aplastic anemia with 2 of the following criteria:\n        Polymorphonuclear neutrophils no more than 0.5 x 10 to the ninth/L Platelets no more than\n        20 x 10 to the ninth/L Reticulocytes no more than 30 x 10 to the ninth/L Hypocellular bone\n        marrow Related donor aged 6 weeks or more, matching at least 4 of 6 HLA A, B, and DRI\n        loci, as follows: HLA-identical family member for patients aged less than 40 years\n        HLA-nonidentical family member for patients aged less than 55 years failing antithymocyte\n        globulin or other immunosuppressive therapy The following eligible for transplantation as\n        initial therapy: Patients aged less than 40 years with HLA-matched donor Patients aged\n        40-45 years with HLA-identical donor No neoplastic or preneoplastic evolution --Patient\n        Characteristics-- Age: Under 40 (55 if ATG failure) Hepatic: No severe liver dysfunction\n        Renal: No severe renal dysfunction Cardiovascular: No severe cardiac dysfunction Other: No\n        other organ dysfunction that would compromise survival after transplant No HIV infection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "10", 
        "firstreceived_date": "October 18, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004323", 
            "org_study_id": "199/11863", 
            "secondary_id": "UCLA-94020602"
        }, 
        "intervention": [
            {
                "intervention_name": "anti-thymocyte globulin", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "cyclophosphamide", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "cyclosporine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "mesna", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "methotrexate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "methylprednisolone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antilymphocyte Serum", 
                "Cyclophosphamide", 
                "Cyclosporins", 
                "Cyclosporine", 
                "Methotrexate", 
                "Methylprednisolone Hemisuccinate", 
                "Prednisolone", 
                "Methylprednisolone acetate", 
                "Prednisolone acetate", 
                "Methylprednisolone", 
                "Prednisolone hemisuccinate", 
                "Prednisolone phosphate"
            ]
        }, 
        "keyword": [
            "aplastic anemia", 
            "hematologic disorders", 
            "rare disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90024-1714"
                }, 
                "name": "Center for Health Sciences"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "overall_official": {
            "affiliation": "University of California, Los Angeles", 
            "last_name": "Mary Carol Territo", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004323"
        }, 
        "source": "National Center for Research Resources (NCRR)", 
        "sponsors": {
            "collaborator": {
                "agency": "University of California, Los Angeles", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Center for Research Resources (NCRR)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "February 1995", 
        "study_design": "Endpoint Classification: Efficacy Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2002"
    }, 
    "geocoordinates": {
        "Center for Health Sciences": "34.052 -118.244"
    }
}